Physician profile
Kenneth Porter
NPI 1174639645
$1,200.39
in general payments reported to CMS, 2019-2025
22 companies · $112 in 2025
The $112 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $368 · 2020: $181 · 2021: $104 · 2022: $119 · 2023: $160 · 2024: $156 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $428.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $197.12 | 2020-2025 | Doc Band |
| Amgen INC. | $115.16 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $114.85 | 2019 | |
| Pfizer INC. | $101.16 | 2019-2023 | |
| Sanofi Pasteur INC. | $90.60 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.24 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $59.55 | 2024-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $59.41 | 2019 | |
| Bio-Rad Laboratories, INC. | $59.09 | 2020 | |
| Phadia US INC. | $48.37 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $32.96 | 2024 | |
| Dexcom, INC. | $28.90 | 2025 | Dexcom G6 Transmitter |
| Sobi, INC | $27.09 | 2019-2021 | |
| Genentech USA, INC. | $24.98 | 2019-2020 | |
| Corium, LLC | $23.71 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $22.42 | 2019 | |
| Exact Sciences Corporation | $22.16 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $20.45 | 2024 | Spravato |
| Glaxosmithkline, LLC. | $18.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.89 | 2023 | Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $14.46 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.19 | 2023 | Fasenra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.